TCRαβ+ T-cell/CD19+ B-cell Depleted Hematopoietic Grafts and a Reduced Intensity Preparative Conditioning Regimen Containing JSP191 to Achieve Engraftment and Blood Reconstitution in Patients With Fanconi Anemia

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Briquilimab (Primary) ; Antithymocyte globulin; Cyclophosphamide; Fludarabine; Rituximab
Indications Fanconi's anaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

06 Apr 2025 Planned End Date changed from 1 Apr 2028 to 1 Dec 2027.
06 Apr 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Dec 2025.
15 Mar 2024 According to Jasper Therapeutics media release, data from the study were presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight